权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Blood Flow MRI for Monitoring of Renal Cell Carcinoma

血流 MRI 监测肾细胞癌

基本信息

批准号：
7282698
负责人：
DAVID Charles ALSOP
金额：
$ 29.3万
依托单位：
BETH ISRAEL DEACONESS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-08-15 至 2010-01-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7282698
关键词：
Abdomen Acceleration Angiogenesis Inhibitors Animal Model Animals Aorta Arts Blood Blood Vessels Blood flow Brain Brain imaging Cancer Center Cardiac Chest Clinical Clinical Research Clinical Trials Detection Development Dopamine Agonists Evaluation Fenoldopam Future Glioma Goals Growth Human Image Interleukin-24 Intervention Intestines Investigational Therapies Israel Kidney Label Magnetic Resonance Imaging Malignant Neoplasms Maps Measurement Measures Medical center Methods Modification Monitor Morphologic artifacts Motion Neoplasm Metastasis Numbers Outcome Pancreas Patient Monitoring Patients Pelvis Peristalsis Physiologic pulse Preparation Pulse taking Qualifying Recurrent tumor Renal Blood Flow Renal Cell Carcinoma Renal carcinoma Reproducibility Reproduction spores Research Research Personnel Respiration Role playing therapy Scanning Signal Transduction Slice Solutions Source Spin Labels Spleen Standards of Weights and Measures Techniques Testing Therapeutic Time Tissues Treatment Failure Validation Vascular Endothelial Growth Factor Receptor Vascular Endothelial Growth Factors Vascular blood supply Vasodilator Agents angiogenesis antiangiogenesis therapy base blood flow measurement cancer therapy density experience human study improved kidney cortex magnetic field novel outcome forecast programs prototype respiratory response success tool tumor tumor growth tumor vascular supply volunteer

项目摘要

DESCRIPTION (provided by applicant): Tumor blood flow is an important indicator of aggressiveness and prognosis. Recent research has emphasized that the ability to generate new blood vessels to supply a growing tumor, or angiogenesis, is a fundamental determinant of tumor viability and expansion. New therapies which aim to block angiogenesis have achieved startling success in animal studies and show promise in human trials. Evaluation of response to such agents in initial human studies would be greatly aided by the availability of techniques for noninvasive measurement of their effects. Since the target of antiangiogenesis is to block the expansion of blood supply, measurement of tumor blood flow should be an early and powerful indicator of response to therapy. Current methods for blood flow imaging and measurement in the body are quite limited, however. We propose to further develop and test an MRI method for imaging of blood flow. While more well-developed for imaging of the brain, the technique has not been fully optimized and evaluated for imaging within the body. We propose to fully optimize and evaluate this method for the imaging of blood flow in the abdomen and pelvis. First we will optimize blood flow measurement in a single slice and determine the timing and signal parameters necessary for reproducible and accurate results. Next we will implement methods to image a volume of the abdomen and pelvis in a short period of time. Finally, we will use the optimized method to measure blood flow in patients with renal cell carcinoma, to evaluate the reproducibility and accuracy of the blood flow measurement, and to measure modulations in kidney blood flow induced by a renal vasodilator. These studies will provide the necessary experience and validation to best use the MRI blood flow method for monitoring of patient response in studies of new experimental therapies. This research will improve and test a technique for making pictures of blood flow into tumors using MRI. Many new treatments for cancer try to stop tumor growth by restricting its blood supply. This MRI technique, if properly developed, may be useful for seeing whether these treatments are effective in some patients and for detecting failure of the treatment as early as possible so more effective treatments can be used.

描述（由申请人提供）：肿瘤血流是侵袭性和预后的重要指标。最近的研究强调，产生新血管以供应生长中的肿瘤或血管生成的能力是肿瘤存活和扩张的基本决定因素。旨在阻断血管生成的新疗法在动物研究中取得了惊人的成功，并在人体试验中显示出希望。在最初的人类研究中，对这些药物的反应进行评估将大大有助于无创测量其影响的技术的可用性。由于抗血管生成的目标是阻断血液供应的扩张，因此测量肿瘤血流量应该是对治疗反应的早期和有力的指标。然而，目前用于体内血流成像和测量的方法相当有限。我们建议进一步开发和测试用于血流成像的MRI方法。虽然该技术在大脑成像方面发展得更好，但该技术尚未完全优化和评估体内成像。我们建议充分优化和评估这种方法在腹部和骨盆的血流成像。首先，我们将优化单个切片中的血流测量，并确定可重现和准确结果所需的时间和信号参数。接下来，我们将实现在短时间内对腹部和骨盆的体积进行成像的方法。最后，我们将使用优化的方法来测量肾细胞癌患者的血流量，以评估血流量测量的可重复性和准确性，并测量由肾血管扩张剂引起的肾血流量的调制。这些研究将提供必要的经验和验证，以便在新的实验性治疗研究中最好地使用MRI血流方法监测患者反应。这项研究将改进和测试一种使用MRI拍摄肿瘤血流图像的技术。许多新的癌症治疗方法试图通过限制血液供应来阻止肿瘤生长。这种MRI技术，如果开发得当，可能有助于了解这些治疗方法是否对某些患者有效，并尽早检测治疗失败，以便使用更有效的治疗方法。